Erratum: Distinct Roles of Type i and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections (PLoS Pathogens (2016) 12:4 (e1005600) DOI: 10.1371/journal.ppat.1005600);Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Lin, Jian Da ^a   Feng, Ningguo ^b,c   Sen, Adrish ^b,c   Balan, Murugabaskar ^a,f   Tseng, Hsiang Chi ^a   McElrath, Constance ^a   Smirnov, Sergey V ^a   Peng, Jianya ^a   Yasukawa, Linda L ^b,c   Durbin, Russell K ^d   Durbin, Joan E ^a,d,e   Greenberg, Harry B ^b,c   Kotenko, Sergei V ^a,d,e  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d The State University of New Jersey   (United States)

^e University of Medicine and Dentistry of New Jersey   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; STAT1 PROTEIN; INTERFERON;

ADAPTIVE IMMUNITY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FOCUS FORMING ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFECTION CONTROL; INFECTIOUS DIARRHEA; INTESTINE EPITHELIUM CELL; INTESTINE INFECTION; MOUSE; NEWBORN; NONHUMAN; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ROTAVIRUS INFECTION; TRANSCRIPTION REGULATION; VIRAL CLEARANCE; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOBLOTTING; IMMUNOLOGY; INTESTINE; KNOCKOUT MOUSE; POLYMERASE CHAIN REACTION; ROTAVIRUS;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; INTERFERON-GAMMA; INTESTINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; ROTAVIRUS; ROTAVIRUS INFECTIONS;

EID: 84964856244     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005726     Document Type: Erratum

References (55)

1. Ramig RF, Pathogenesis of intestinal and systemic rotavirus infection. J Virol. 2004;78(19):10213–20. Epub 2004/09/16. doi: 10.1128/JVI.78.19.10213–10220.2004 78/19/10213 [pii]. 15367586.
2. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136–41. Epub 2011/10/28. doi: S1473-3099(11)70253-5 [pii] doi: 10.1016/S1473-3099(11)70253-522030330.
3. Mossel EC, Ramig RF, Rotavirus genome segment 7 (NSP3) is a determinant of extraintestinal spread in the neonatal mouse. J Virol. 2002;76(13):6502–9. Epub 2002/06/07. 12050363.
4. Mossel EC, Ramig RF, A lymphatic mechanism of rotavirus extraintestinal spread in the neonatal mouse. J Virol. 2003;77(22):12352–6. Epub 2003/10/29. 14581572.
5. Fenaux M, Cuadras MA, Feng N, Jaimes M, Greenberg HB, Extraintestinal spread and replication of a homologous EC rotavirus strain and a heterologous rhesus rotavirus in BALB/c mice. J Virol. 2006;80(11):5219–32. Epub 2006/05/16. doi: 80/11/5219 [pii] doi: 10.1128/JVI.02664-0516699002.
6. Sen A, Rothenberg ME, Mukherjee G, Feng N, Kalisky T, Nair N, et al. Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci U S A. 2012;109(50):20667–72. Epub 2012/11/29. doi: 1212188109 [pii] doi: 10.1073/pnas.121218810923188796.
7. Lazear HM, Nice TJ, Diamond MS, Interferon-lambda: Immune Functions at Barrier Surfaces and Beyond. Immunity. 2015;43(1):15–28. Epub 2015/07/23. doi: S1074-7613(15)00268-X [pii] doi: 10.1016/j.immuni.2015.07.00126200010.
8. Durbin RK, Kotenko SV, Durbin JE, Interferon induction and function at the mucosal surface. Immunol Rev. 2013;255(1):25–39. Epub 2013/08/21. doi: 10.1111/imr.1210123947345.
9. Wack A, Terczynska-Dyla E, Hartmann R, Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16(8):802–9. Epub 2015/07/22. doi: ni.3212 [pii] doi: 10.1038/ni.321226194286.
10. Deal EM, Lahl K, Narvaez CF, Butcher EC, Greenberg HB, Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses. J Clin Invest. 2013;123(6):2464–74. Epub 2013/05/03. doi: 60945 [pii] doi: 10.1172/JCI6094523635775.
11. Holloway G, Coulson BS, Innate cellular responses to rotavirus infection. J Gen Virol. 2013;94(Pt 6):1151–60. Epub 2013/03/15. doi: vir.0.051276–0 [pii] doi: 10.1099/vir.0.051276–023486667.
12. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77. Epub 2002/12/17. doi: 10.1038/ni87512483210.
13. Kotenko SV, IFN-lambdas. Curr Opin Immunol. 2011;23(5):583–90. Epub 2011/08/16. doi: S0952-7915(11)00080-X [pii] doi: 10.1016/j.coi.2011.07.00721840693.
14. Donnelly RP, Kotenko SV, Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 2010;30(8):555–64. Epub 2010/08/18. doi: 10.1089/jir.2010.007820712453.
15. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887–98. Epub 2006/11/08. doi: S0016-5085(06)02220-7 [pii] doi: 10.1053/j.gastro.2006.09.05217087946.
16. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC, . Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004;279(31):32269–74. Epub 2004/05/29. doi: 10.1074/jbc.M40478920015166220.
17. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006;44(4):896–906. Epub 2006/09/29. doi: 10.1002/hep.2131217006906.
18. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–8. Epub 2002/12/07. doi: 10.1038/ni87312469119.
19. Sommereyns C, Paul S, Staeheli P, Michiels T, . IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3):e1000017. Epub 2008/03/29. doi: 10.1371/journal.ppat.100001718369468.
20. Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P, Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015;11(4):e1004782. Epub 2015/04/08. doi: 10.1371/journal.ppat.1004782 PPATHOGENS-D-14-01959 [pii]. 25849543.
21. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015;347(6219):269–73. Epub 2014/11/29. doi: science.1258100 [pii] doi: 10.1126/science.125810025431489.
22. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A. 2011;108(19):7944–9. Epub 2011/04/27. doi: 1100552108 [pii] doi: 10.1073/pnas.110055210821518880.
23. Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat Immunol. 2015;16(7):698–707. Epub 2015/05/26. doi: ni.3180 [pii] doi: 10.1038/ni.318026006013.
24. Vancott JL, McNeal MM, Choi AH, Ward RL, The role of interferons in rotavirus infections and protection. J Interferon Cytokine Res. 2003;23(3):163–70. Epub 2003/04/30. doi: 10.1089/10799900332153250112716489.
25. Feng N, Kim B, Fenaux M, Nguyen H, Vo P, Omary MB, et al. Role of interferon in homologous and heterologous rotavirus infection in the intestines and extraintestinal organs of suckling mice. J Virol. 2008;82(15):7578–90. Epub 2008/05/23. doi: JVI.00391-08 [pii] doi: 10.1128/JVI.00391-0818495762.
26. Feng N, Yasukawa LL, Sen A, Greenberg HB, Permissive replication of homologous murine rotavirus in the mouse intestine is primarily regulated by VP4 and NSP1. J Virol. 2013;87(15):8307–16. Epub 2013/05/24. doi: JVI.00619-13 [pii] doi: 10.1128/JVI.00619-1323698306.
27. Sen A, Rott L, Phan N, Mukherjee G, Greenberg HB, Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation. J Virol. 2014;88(1):41–53. Epub 2013/10/18. doi: JVI.01501-13 [pii] doi: 10.1128/JVI.01501-1324131713.
28. Cortese MM, Immergluck LC, Held M, Jain S, Chan T, Grizas AP, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics. 2013;132(1):e25–33. Epub 2013/06/19. doi: peds.2012-3804 [pii] doi: 10.1542/peds.2012-380423776114.
29. Zhen SS, Li Y, Wang SM, Zhang XJ, Hao ZY, Chen Y, et al. Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg Microbes Infect. 2015;4(10):e64. Epub 2015/11/18. doi: 10.1038/emi.2015.6426576341.
30. Arnold MM, Sen A, Greenberg HB, Patton JT, The battle between rotavirus and its host for control of the interferon signaling pathway. PLoS Pathog. 2013;9(1):e1003064. Epub 2013/01/30. doi: 10.1371/journal.ppat.1003064 PPATHOGENS-D-12-02249 [pii]. 23359266.
31. Barro M, Patton JT, Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3. Proc Natl Acad Sci U S A. 2005;102(11):4114–9. Epub 2005/03/03. doi: 0408376102 [pii] doi: 10.1073/pnas.040837610215741273.
32. Barro M, Patton JT, Rotavirus NSP1 inhibits expression of type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J Virol. 2007;81(9):4473–81. Epub 2007/02/16. doi: JVI.02498-06 [pii] doi: 10.1128/JVI.02498-0617301153.
33. Greenberg HB, Vo PT, Jones R, Cultivation and characterization of three strains of murine rotavirus. J Virol. 1986;57(2):585–90. Epub 1986/02/01. 3003390.
34. Sen A, Feng N, Ettayebi K, Hardy ME, Greenberg HB, IRF3 inhibition by rotavirus NSP1 is host cell and virus strain dependent but independent of NSP1 proteasomal degradation. J Virol. 2009;83(20):10322–35. Epub 2009/08/07. doi: JVI.01186-09 [pii] doi: 10.1128/JVI.01186-0919656876.
35. Kang G, Iturriza-Gomara M, Wheeler JG, Crystal P, Monica B, Ramani S, et al. Quantitation of group A rotavirus by real-time reverse-transcription-polymerase chain reaction: correlation with clinical severity in children in South India. J Med Virol. 2004;73(1):118–22. Epub 2004/03/26. doi: 10.1002/jmv.2005315042658.
36. Pulit-Penaloza JA, Scherbik SV, Brinton MA, Type 1 IFN-independent activation of a subset of interferon stimulated genes in West Nile virus Eg101-infected mouse cells. Virology. 2012;425(2):82–94. Epub 2012/02/07. doi: S0042-6822(12)00022-0 [pii] doi: 10.1016/j.virol.2012.01.00622305622.
37. Andersen J, VanScoy S, Cheng TF, Gomez D, Reich NC, IRF-3-dependent and augmented target genes during viral infection. Genes Immun. 2008;9(2):168–75. Epub 2007/12/21. doi: 6364449 [pii] doi: 10.1038/sj.gene.636444918094709.
38. Zhang B, Chassaing B, Shi Z, Uchiyama R, Zhang Z, Denning TL, et al. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. Science. 2014;346(6211):861–5. Epub 2014/11/15. doi: 346/6211/861 [pii] doi: 10.1126/science.125699925395539.
39. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol. 2010;84(21):11515–22. Epub 2010/08/27. doi: JVI.01703-09 [pii] doi: 10.1128/JVI.01703-0920739515.
40. Yun NE, Seregin AV, Walker DH, Popov VL, Walker AG, Smith JN, et al. Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J Virol. 2013;87(19):10908–11. Epub 2013/08/02. doi: JVI.01433-13 [pii] doi: 10.1128/JVI.01433-1323903830.
41. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008;4(9):e1000151. Epub 2008/09/13. doi: 10.1371/journal.ppat.100015118787692.
42. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84(11):5670–7. Epub 2010/03/26. doi: JVI.00272-10 [pii] doi: 10.1128/JVI.00272-1020335250.
43. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 2013;9(11):e1003773. Epub 2013/11/28. doi: doi: 10.1371/journal.ppat.1003773 PPATHOGENS-D-13-00283 [pii]. 24278020.
44. Horisberger MA, Staeheli P, Haller O, Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc Natl Acad Sci U S A. 1983;80(7):1910–4. Epub 1983/04/01. 6188159.
45. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008;180(4):2474–85. Epub 2008/02/06. doi: 180/4/2474 [pii]. 18250457.
46. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity. 2012;37(1):158–70. Epub 2012/06/19. doi: S1074-7613(12)00237-3 [pii] doi: 10.1016/j.immuni.2012.04.01122705104.
47. Caballero S, Pamer EG, Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol. 2015;33:227–56. Epub 2015/01/13. doi: 10.1146/annurev-immunol-032713-12023825581310.
48. Uchiyama R, Chassaing B, Zhang B, Gewirtz AT, Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J Infect Dis. 210(2):171–82. Epub 2014/01/18. [pii] doi: 10.1093/infdis/jiu03724436449.
49. Burns JW, Krishnaney AA, Vo PT, Rouse RV, Anderson LJ, Greenberg HB, Analyses of homologous rotavirus infection in the mouse model. Virology. 1995;207(1):143–53. Epub 1995/02/20. doi: S0042-6822(85)71060-4 [pii] doi: 10.1006/viro.1995.10607871723.
50. Ciarlet M, Conner ME, Finegold MJ, Estes MK, Group A rotavirus infection and age-dependent diarrheal disease in rats: a new animal model to study the pathophysiology of rotavirus infection. J Virol. 2002;76(1):41–57. Epub 2001/12/12. 11739670.
51. Wolf JL, Cukor G, Blacklow NR, Dambrauskas R, Trier JS, Susceptibility of mice to rotavirus infection: effects of age and administration of corticosteroids. Infect Immun. 1981;33(2):565–74. Epub 1981/08/01. 6268547.
52. Angel J, Franco MA, Greenberg HB, Bass D, Lack of a role for type I and type II interferons in the resolution of rotavirus-induced diarrhea and infection in mice. J Interferon Cytokine Res. 1999;19(6):655–9. Epub 1999/08/05. doi: 10.1089/10799909931380210433367.
53. Yoshie O, Aso H, Sakakibara A, Ishida N, Differential effects of recombinant human interferon-alpha A/D on expression of three types of Fc receptors on murine macrophages in vivo and in vitro. J Interferon Res. 1985;5(4):531–40. Epub 1985/01/01. 4086883.
54. Feng N, Burns JW, Bracy L, Greenberg HB, Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J Virol. 1994;68(12):7766–73. Epub 1994/12/01. 7966566.
55. Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, Cros J, Mertz SE, Jewell NA, et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol. 2006;80(3):1130–9. Epub 2006/01/18. doi: 80/3/1130 [pii] doi: 10.1128/JVI.80.3.1130–1139.200616414990.